Synthetic peptidePCAC 2026BPC-157Synthetic pentadecapeptide (15 amino acids).
Fragment / analogPCAC 2026TB-500Synthetic peptide related to a fragment of thymosin β4.
Peptide–metal complexGHK-CuCopper(II) complex of the tripeptide Gly-His-Lys.
Fragment / analogPCAC 2026KPVTripeptide (Lys-Pro-Val), the C-terminal sequence of α-MSH.
Mitochondrial-derived peptidePCAC 2026MOTS-c16-amino-acid peptide encoded in mitochondrial DNA.
Synthetic peptidePCAC 2026EpitalonSynthetic tetrapeptide (Ala-Glu-Asp-Gly).
Fragment / analogPCAC 2026SemaxSynthetic heptapeptide derived from an ACTH fragment.
Fragment / analogSelankSynthetic heptapeptide analog of tuftsin.
Synthetic peptideThymosin α128-amino-acid peptide; also listed as TA-1.
Synthetic peptideIpamorelinSynthetic pentapeptide.
Fragment / analogCJC-1295Synthetic GHRH(1-29) analog. Characterized in rats (Jetté et al., Endocrinology 2005); studied in a GHRH-knockout mouse model (Alba et al., Am J Physiol Endocrinol Metab 2006) and in healthy adult volunteers (Teichman et al., J Clin Endocrinol Metab 2006).
For research use only. Not for human consumption.
Coenzyme (non-peptide)NAD+Nicotinamide adenine dinucleotide, a dinucleotide coenzyme.
“PCAC 2026” marks compounds reviewed at the July 2026 FDA Pharmacy Compounding Advisory Committee meeting. That review concerns pharmacy compounding only. It does not indicate approval or authorize human use of research materials.